AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 41 min read$HALO

Torley Helen sold $137K of HALO

Torley Helen (PRESIDENT AND CEO) sold 2,000 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $68.74 ($0.14M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Torley Helen
Published Jun 4, 2026, 12:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HALO
Neutral
high confidence
Mentioned
$HALO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HALONeutralLow
01

Why it matters

No new fundamental information is provided; the disclosure mainly informs about insider activity and potential sentiment/positioning.

02

Market read

Traders may briefly reassess sentiment, but the 10b5-1 framing suggests limited directional impact.

03

What to watch

The sale size ($137k) is small relative to typical institutional float, and the plan being pre-arranged reduces informational content.

Relevance 4/10Novelty 2/10Timing: Filed 2026-06-03 after-hours; reflects sale executed on 2026-06-03.

Background

The article is an SEC EDGAR Form 4 disclosure of an insider’s transaction (officer/CEO) for Halozyme Therapeutics.

Company-level read

Ticker impact

$HALONeutralHigh confidence
Context

SEC Form 4 shows HALO CEO Torley Helen sold 2,000 shares on 2026-06-03 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; watch for any unusual follow-through in volume rather than a directional fundamental move.

Evidence & confidence

The filing is a routine, pre-arranged open-market sale by an officer; no new company-specific operational or financial catalyst is disclosed.

Market effects

Sector

Minimal—single-company insider transaction without new guidance or trial/regulatory updates.

Regional

None indicated; US-listed micro/biotech flow only.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with periods of perceived valuation risk; traders may treat it as a mild caution flag if paired with other negative signals.

Key entities

  • public_company
    HALO

    Issuer of the securities sold by the CEO under a 10b5-1 plan.

  • insider
    Torley Helen

    President and CEO who executed an open-market sale of 2,000 shares.

Read at source← All news

Related articles

AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min
AUG 7
$HALOHighAI 9/10

Halozyme climbs after record Q2 results and higher 2026 outlook

Halozyme Therapeutics (HALO) shares rose about 15% after the company reported record Q2 2026 results and raised 2026 guidance, according to Halozyme’s investor release. Q2 total revenue increased 48% to $481 million, royalty revenue rose 50% to $307.7 million. Full-year 2026 revenue guidance was raised to $1.835B-$1.910B and non-GAAP diluted EPS to $8.65-$9.00.

quiverquant.com4 min
AUG 7
$HALOHighAI 9/10

Why is Halozyme Therapeutics stock surging today?

Halozyme Therapeutics shares rose about 6.1% pre-open after the company reported record Q2 2026 results. Total revenue increased 48% to $481 million and non-GAAP EPS was $2.28, both above expectations. Royalty revenue hit $307.7 million. Halozyme raised full-year 2026 guidance to non-GAAP EPS of $8.65-$9.00 and revenue of $1.835-$1.910 billion, and said it signed five new ENHANZE/Hypercon deals year-to-date.

investing.com2 min
AUG 7
$HALOMedAI 8/10

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported Q2 royalty momentum for VYVGART Hytrulo, with royalty revenue up 143% to $72.6M and total VYVGART brand sales up 60% to $1.5B. Other royalty revenue rose 85% to $54.4M. Halozyme raised 2026 guidance to $1.835B-$1.91B revenue and $8.65-$9.00 non-GAAP EPS, and repurchased $332.8M of stock.

yahoo.com6 min